AJCC9V staging system showed superior hazard consistency, outcome prediction, and balance, but not hazard discrimination.

We were able to detect 100% of recurrences by ctDNA ahead of clinical recurrence, which included all lung metastases as well as other distant metastases,” said Emma Titmuss.